Osivax has announced the completion of patient visits in its phase 2a trial evaluating a booster dose of OVX836, a broad-spectrum influenza A vaccine candidate. The final results from the trial are expected in the second half of 2025. Conducted at the centre for vaccinology (CEVAC), Ghent University Hospital, Belgium, the trial investigated the safety […]
The post Osivax reaches key milestone in phase 2a trial for broad-spectrum flu vaccine appeared first on Pharmafile.
